A PET/CT radiomics model for predicting distant metastasis in early-stage non–small cell lung cancer patients treated with stereotactic body radiotherapy: a multicentric study

• DOI: 10.1186/s13014-024-02402-z
• Publication Date: 2024-01-22T08:03:07Z
• Authors: Lu Yu; Zhen Zhang; HeQing Yi; Jin Wang; Junyi Li; Xiaofeng Wang; Hui Bai; Hong Ge; Xiaoli Zheng; Jianjiao Ni; Haoran Qi; Yong Guan; Wengui Xu; Zhengfei Zhu; Ligang Xing; Andre Dekker; Leonard Wee; Alberto Traverso; Zhaoxiang Ye; Zhiyong Yuan
• Keywords: China; Lung Neoplasms; Radiomics; PET/CT; Stereotactic body radiotherapy; Research; R895-920; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; Radiosurgery; Small Cell Lung Carcinoma; Medical physics. Medical radiology. Nuclear medicine; Non-small cell lung cancer; Risk Factors; Carcinoma, Non-Small-Cell Lung; Positron Emission Tomography Computed Tomography; Distant metastasis; Humans; RC254-282

Abstract Objectives Stereotactic body radiotherapy ( SBRT) is a treatment option for patients with early-stage non-small cell lung cancer (NSCLC) who are unfit surgery. Some may experience distant metastasis. This study aimed to develop and validate radiomics model predicting metastasis in NSCLC treated SBRT. Methods Patients at five institutions were enrolled this study. Radiomics features extracted based on the PET/CT images. After feature selection training set (from Tianjin), CT-based PET-based signatures built. Models CT PET built validated using external datasets Zhejiang, Zhengzhou, Shandong, Shanghai). An integrated that included radiomic was developed. The performance of proposed evaluated terms its discrimination, calibration, clinical utility. Multivariate logistic regression used calculate probability metastases. cutoff value obtained receiver operator characteristic curve (ROC), divided into high- low-risk groups. Kaplan-Meier analysis evaluate metastasis-free survival (DMFS) different risk Results In total, 228 enrolled. median follow-up time 31.4 (2.0-111.4) months. had an area under (AUC) 0.819 n = 139) 0.786 dataset 89). AUC 0.763 0.804 dataset. combining 0.835 combined showed moderate calibration positive net benefit. When greater than 0.19, patient considered be high risk. DMFS significantly stratified P < 0.001). Conclusions can predict SBRT provide reference decision-making. Plain language summary study, established by moderate-quantity cohort successfully independent cohorts. Physicians could use easy-to-use assess after Identifying subgroups factors useful guiding personalized approaches.